Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Gossypol and Nitric Oxide

supplement:

Gossypol

Research Papers that Mention the Interaction

All dosages of gossypol used increased the production of NO and all dosages except 200 μM raised the level of apoptosis.
Cell biology international  •  2004  |  View Paper
Furthermore, pre-incubation with gossypol , an inhibitor of the formation and release of endothelium-derived relaxing factors (EDRF), completely abolished the effects of SP without influencing the dilatory action of CGRP.
Acta physiologica Scandinavica  •  1989  |  View Paper
The Ca2+ influx triggered by 3 and 10 µmol/L gossypol caused NO release and cell death, respectively.
Clinical and experimental pharmacology & physiology  •  2018  |  View Paper
Gossypol , an inhibitor of EDRF , virtually abolished the 5-HT-induced relaxation while indometacin, an inhibitor of cyclooxygenase and accordingly of PGI2 formation, did not.
Naunyn-Schmiedeberg's Archives of Pharmacology  •  2004  |  View Paper
Incubation of unrubbed arteries with the irreversible inhibitor of EDRF, gossypol (10(-5) M), significantly increased the contractile response to 5-HT (Emax = 77 +/- 4%).
General pharmacology  •  1993  |  View Paper
5 Gossypol (1–15 μm), a presumed inhibitor of EDRF biosynthesis, caused a marked drop in perfusion pressure followed by vasoconstriction.
British journal of pharmacology  •  1991  |  View Paper
To test whether inhibitors of endothelium-derived relaxation factor would potentiate the myogenic response of 3As, methylene blue or gossypol was topically applied to the cremaster muscle.
The American journal of physiology  •  1990  |  View Paper
Gossypol (10 microM, 5 min), an inhibitor of endothelium-derived relaxing factor (EDRF) production and/or release, increased basal RVR by 5% and significantly inhibited the vasodilator effects of ACh and ATP but had no effect on verapamil- or GTN-induced decreases in RVR.
The American journal of physiology  •  1990  |  View Paper
Two inhibitors of EDRF , methylene blue and gossypol , increased RVR in nonischemic kidneys by 45 +/- 6 and 46 +/- 11%, respectively, an increase that was comparable to that found with ischemia alone (55 +/- 7%).
The American journal of physiology  •  1989  |  View Paper
In vitro, gossypol is an inhibitor of the production and/or release of endothelium-derived relaxing factor.
European journal of pharmacology  •  1988  |  View Paper